PTC Therapeutics Announces APHENITY Trial Achieved Primary Endpoint with Sepiapterin in PKU Patients
- Conference call and webcast to be held at 8:00 AM EDT - SOUTH PLAINFIELD, N.J., May 17, 2023 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the primary endpoint was ...
Credit: Getty Images. The investigational therapy is an oral formulation of synthetic sepiapterin. Sepiapterin significantly reduced blood phenylalanine levels in adult and pediatric patients with ...
Beam Therapeutics (NASDAQ:BEAM) outlined a new liver-targeted development program for phenylketonuria (PKU) and announced a large, non-dilutive financing tied to its sickle cell disease launch plans ...
DEER PARK, Ill., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases ...
The MarketWatch News Department was not involved in the creation of this content. Phenylketonuria Market to Reach New Heights by 2034, Driven by Innovative Therapies and Rising Diagnosis Rates | ...
Researchers in Germany recently evaluated executive functions in 36 patients who were diagnosed with PKU during childhood. Significant negative correlations were observed between elevated childhood ...
When Joni Arneson goes out to eat, she’s not likely to order a steak. For one thing, she doesn’t like meat. But more importantly, an overload of protein could give her a severe headache. Arneson is a ...
Relief Signs a Definitive Agreement to Acquire a Novel Dosage Form of an Already Approved Prescription Drug for the Treatment of PKU 13-Jul-2022 / 07:00 CET/CEST Release of an ad hoc announcement ...
To control their phenylalanine (Phe) levels, patients with PKU are advised to follow a restricted diet. However, little is known about the long-term consequences. A new study of 15 adults with PKU ...
On Friday, the U.S. Food and Drug Administration (FDA) approved BioMarin Pharmaceutical Inc.’s supplemental application for Palynziq (pegvaliase-pqpz), a treatment for phenylketonuria (PKU) in ...
(RTTNews) - PTC Therapeutics, Inc. (PTCT) announced Wednesday that the primary endpoint was achieved in the APHENITY, Phase 3 registration-directed clinical trial of sepiapterin in adult and pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results